Vistance Networks (VISN) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
16 Jan, 2026Executive summary
Net sales for Q3 2024 rose 2.7% year-over-year to $1.082 billion, driven by strong CCS segment performance and market recovery.
Core adjusted EBITDA increased 25% year-over-year to $220 million, with CCS adjusted EBITDA up 115% and margin at 20.4%.
Adjusted EPS improved to $(0.05) from $(0.12) year-over-year; GAAP loss from continuing operations narrowed to $(96.7) million.
The divestiture of OWN and DAS businesses to Amphenol for $2.1 billion is expected to close in Q1 2025, providing capital structure flexibility.
Free cash flow was $115.5 million, and total liquidity exceeded $1.02 billion at quarter end.
Financial highlights
Gross profit for Q3 2024 was $435.1 million, with gross margin improving to 40.2% from 36.1% year-over-year.
Operating income was $102.2 million, a turnaround from a $408.4 million loss in Q3 2023.
Net loss attributable to common stockholders was $(49.4) million, improved from $(844.2) million in Q3 2023.
Adjusted EBITDA for Q3 2024 was $204.2 million, up 30.2% year-over-year.
Cash and cash equivalents stood at $456.4 million as of September 30, 2024.
Outlook and guidance
Full-year 2024 core adjusted EBITDA guidance is $700–$750 million, with break-even free cash flow expected.
Q4 core revenue and adjusted EBITDA expected to be in line with Q3, reflecting normal seasonality.
No 2025 guidance provided due to market uncertainty, but improvement expected as markets recover.
Proceeds from the pending $2.1 billion OWN/DAS sale are expected to address $1.27 billion in senior notes maturing June 2025.
Latest events from Vistance Networks
- Director elections, executive pay, auditor ratification, and incentive plan shares up for vote.VISN
Proxy filing23 Mar 2026 - Proxy outlines director elections, executive pay, auditor ratification, and major ESG progress.VISN
Proxy filing23 Mar 2026 - Core adjusted EBITDA up 176% in 2025; $10/share special distribution planned.VISN
Q4 202526 Feb 2026 - Adjusted EBITDA up nearly 20% as CCS growth offsets declines; $2.1B OWN/DAS sale to aid liquidity.VISN
Q2 20242 Feb 2026 - Core adjusted EBITDA up 159% on 23.5% sales growth; 2025 guidance reaffirmed.VISN
Q1 202524 Dec 2025 - Q4 core sales jumped 27% and margins rose, with 2025 EBITDA guidance at $1.00–$1.05B.VISN
Q4 202421 Dec 2025 - Definitive agreement to sell CCS segment to Amphenol, pending shareholder approval and regulatory review.VISN
Proxy Filing2 Dec 2025 - CCS business sale unlocks equity, enables debt repayment, and sets up a major shareholder dividend.VISN
Proxy Filing1 Dec 2025 - $10.5B sale of CCS segment to Amphenol, pending approvals and board support.VISN
Proxy Filing1 Dec 2025